Mutant IDH1 inhibitors useful for treating cancer

US10703746B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The University of North Carolina at Chapel Hill · US

Inventors

• Matthew B. Boxer · Point of Rocks, US
• Jason Rohde · Poolesville, US
• Rajan Pragani · Rockville, US
• Li Liu · Doylestown, US
• Mindy Irene Emily Davis · Rockville, US
• Kyle Ryan Brimacombe · Bethesda, US
• Min-Jui Richard Shen · Boyds, US
• Anton Simeonov · Rockville, US
• Surendra Karavadhi · Gaithersburg, US
• Daniel Jason Urban · Rockville, US
• Ajit Jadhav · Chantilly, US
• Xiaodong Wang · Zhejiang, CN
• Andrew Louis McIver · Durham, US

Key dates

• Filing date: Dec 22, 2015
• Grant date: Jul 7, 2020
• Expiry date: May 4, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.